BR112018012618A2 - composições da nano emulsão de fluorocarbonos e métodos de preparação e uso dos mesmos - Google Patents
composições da nano emulsão de fluorocarbonos e métodos de preparação e uso dos mesmosInfo
- Publication number
- BR112018012618A2 BR112018012618A2 BR112018012618A BR112018012618A BR112018012618A2 BR 112018012618 A2 BR112018012618 A2 BR 112018012618A2 BR 112018012618 A BR112018012618 A BR 112018012618A BR 112018012618 A BR112018012618 A BR 112018012618A BR 112018012618 A2 BR112018012618 A2 BR 112018012618A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- preparation
- nanoemulsion compositions
- fluorocarbon nanoemulsion
- fluorocarbon
- Prior art date
Links
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000007908 nanoemulsion Substances 0.000 title abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 150000003904 phospholipids Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L27/00—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a halogen; Compositions of derivatives of such polymers
- C08L27/02—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a halogen; Compositions of derivatives of such polymers not modified by chemical after-treatment
- C08L27/12—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a halogen; Compositions of derivatives of such polymers not modified by chemical after-treatment containing fluorine atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Nanotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Hematology (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Polymers & Plastics (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Abstract
a presente invenção refere-se às novas composições de nano emulsões de fluorocarbonos compreendendo um ou mais de fluorotensoativos e fosfolipídios, e métodos de preparação e uso dos mesmos para o fornecimento de oxigênio melhorado.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562270226P | 2015-12-21 | 2015-12-21 | |
PCT/US2016/067650 WO2017112614A1 (en) | 2015-12-21 | 2016-12-20 | Compositions of fluorocarbon nanoemulsion, and methods of preparation and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018012618A2 true BR112018012618A2 (pt) | 2018-12-04 |
Family
ID=59089857
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018012618A BR112018012618A2 (pt) | 2015-12-21 | 2016-12-20 | composições da nano emulsão de fluorocarbonos e métodos de preparação e uso dos mesmos |
Country Status (11)
Country | Link |
---|---|
US (2) | US11304899B2 (pt) |
EP (1) | EP3393459A4 (pt) |
JP (1) | JP6936226B2 (pt) |
KR (1) | KR20180132605A (pt) |
CN (1) | CN108697664A (pt) |
AU (2) | AU2016377361B2 (pt) |
BR (1) | BR112018012618A2 (pt) |
CA (1) | CA3009404C (pt) |
EA (1) | EA201891296A1 (pt) |
IL (2) | IL260206B2 (pt) |
WO (1) | WO2017112614A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102342326B1 (ko) * | 2020-12-11 | 2021-12-23 | 애경케미칼주식회사 | 계면장력이 우수한 불소계 계면활성제 조성물 |
KR102342324B1 (ko) * | 2020-12-11 | 2021-12-23 | 애경케미칼주식회사 | 불소계 계면활성제 조성물 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5558855A (en) * | 1993-01-25 | 1996-09-24 | Sonus Pharmaceuticals | Phase shift colloids as ultrasound contrast agents |
US5846517A (en) | 1996-09-11 | 1998-12-08 | Imarx Pharmaceutical Corp. | Methods for diagnostic imaging using a renal contrast agent and a vasodilator |
US20060003012A9 (en) * | 2001-09-26 | 2006-01-05 | Sean Brynjelsen | Preparation of submicron solid particle suspensions by sonication of multiphase systems |
CN104039316A (zh) * | 2011-03-04 | 2014-09-10 | 阿肯色大学评议会 | 作为中风和局部缺血治疗的十二氟戊烷乳液 |
US10279053B2 (en) * | 2011-07-19 | 2019-05-07 | Nuvox Pharma Llc | Microbubble compositions, method of making same, and method using same |
WO2013043236A1 (en) * | 2011-09-22 | 2013-03-28 | Rockland Technimed, Ltd. | Compositions and methods useful for realtime in situ physiological molecular imaging of oxygen metabolism |
US8822549B2 (en) * | 2011-10-13 | 2014-09-02 | Jennifer L. Johnson | Buffered oxygen therapeutic |
CN106488766A (zh) | 2014-03-05 | 2017-03-08 | 埃文·C·昂格尔 | 利用氧气疗法的分割放疗和化疗 |
US9801959B2 (en) | 2014-06-12 | 2017-10-31 | Microvascuar Therapeutics Llc | Phospholipid composition and microbubbles and emulsions formed using same |
JP6803839B2 (ja) * | 2014-12-18 | 2020-12-23 | ブラッコ・スイス・ソシエテ・アノニムBracco Suisse SA | 標的化されたガス入りの微小胞の製剤 |
-
2016
- 2016-12-20 KR KR1020187020326A patent/KR20180132605A/ko active IP Right Grant
- 2016-12-20 EP EP16879945.0A patent/EP3393459A4/en active Pending
- 2016-12-20 EA EA201891296A patent/EA201891296A1/ru unknown
- 2016-12-20 IL IL260206A patent/IL260206B2/en unknown
- 2016-12-20 JP JP2018531107A patent/JP6936226B2/ja active Active
- 2016-12-20 US US16/060,950 patent/US11304899B2/en active Active
- 2016-12-20 BR BR112018012618A patent/BR112018012618A2/pt not_active Application Discontinuation
- 2016-12-20 IL IL298236A patent/IL298236B2/en unknown
- 2016-12-20 CA CA3009404A patent/CA3009404C/en active Active
- 2016-12-20 AU AU2016377361A patent/AU2016377361B2/en active Active
- 2016-12-20 CN CN201680081126.3A patent/CN108697664A/zh active Pending
- 2016-12-20 WO PCT/US2016/067650 patent/WO2017112614A1/en active Application Filing
-
2022
- 2022-04-15 US US17/721,445 patent/US20220401364A1/en active Pending
- 2022-09-21 AU AU2022235555A patent/AU2022235555A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2017112614A1 (en) | 2017-06-29 |
EP3393459A1 (en) | 2018-10-31 |
EP3393459A4 (en) | 2019-10-02 |
US11304899B2 (en) | 2022-04-19 |
IL260206A (en) | 2018-07-31 |
AU2016377361A1 (en) | 2018-07-05 |
CA3009404A1 (en) | 2017-06-29 |
US20180360754A1 (en) | 2018-12-20 |
IL298236A (en) | 2023-01-01 |
IL298236B1 (en) | 2024-01-01 |
IL260206B (en) | 2022-12-01 |
AU2022235555A1 (en) | 2022-10-13 |
KR20180132605A (ko) | 2018-12-12 |
EA201891296A1 (ru) | 2019-01-31 |
JP6936226B2 (ja) | 2021-09-15 |
US20220401364A1 (en) | 2022-12-22 |
CN108697664A (zh) | 2018-10-23 |
IL260206B2 (en) | 2023-04-01 |
JP2019502682A (ja) | 2019-01-31 |
CA3009404C (en) | 2023-12-12 |
AU2016377361B2 (en) | 2022-07-07 |
IL298236B2 (en) | 2024-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112016024644A2 (pt) | vacinas de ácido nucleico | |
BR112018073384A2 (pt) | polinucleotídeos moduladores | |
CY1123953T1 (el) | Καθυστερημενης απελευθερωσης συνθεσεις λινακλοτιδης | |
BR112019000338A2 (pt) | composições compreendendo cepas bacterianas | |
BR112018010720A8 (pt) | agonistas do receptor de apelina e métodos de uso | |
BR112017023161A2 (pt) | composições de ácido obeticólico e métodos de uso | |
MX2017004838A (es) | Composiciones de interleucina-15 y usos de estas. | |
BR112014029706A8 (pt) | Composto, composição farmacêutica, e, uso de um composto | |
CR20160502A (es) | Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso | |
BR112017003346A2 (pt) | derivados de pirazolopiridina, seus usos, e composição farmacêutica | |
MX2021010060A (es) | Produccion de virus en huevos aviares. | |
MX2017004975A (es) | Composiciones de anticuerpos anti-il-7r. | |
MY184381A (en) | Stable formulations of lipids and liposomes | |
BR112017009545B8 (pt) | Composição antibacteriana farmacêutica ou veterinária e método in vitro para a preparação de uma composição farmacêutica ou veterinária | |
BR112016024096A2 (pt) | novo bacteriófago e composição compreendendo o mesmo | |
BR112017015159A2 (pt) | preparação e uso de produtos plaquetários | |
BR112018012313A2 (pt) | composições que compreendem 15-hepe e métodos para uso das mesmas | |
BR112017017310A2 (pt) | composições lipídicas | |
MX2019005102A (es) | Poxvirus quimericos sinteticos. | |
IN2014CH00840A (pt) | ||
BR112017008867A2 (pt) | inibidores de proteína quinases | |
BR112018074910A2 (pt) | composição imunológica, e, método de indução de uma resposta imunológica contra o vírus da influenza equina em um sujeito | |
BR112015032388A2 (pt) | métodos e composições para as vacinas contra o vírus da dengue | |
BR112018010692A8 (pt) | composições imunoestimuladoras, usos de melanina ou de um precursor da melanina e método para obter uma composição imunoestimuladora | |
BR112018012618A2 (pt) | composições da nano emulsão de fluorocarbonos e métodos de preparação e uso dos mesmos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |